Featured Research

from universities, journals, and other organizations

A Clear View Of Mycobacterial Infection

Date:
November 5, 2004
Source:
Public Library Of Science
Summary:
Fighting an infection might seem to be a battle between David and Goliath, given the relative sizes of bacterial infectious agents and the animals they infect. But on closer examination it is more often a chess match between two skilled opponents who have the uncanny ability to anticipate each other's moves.

Fighting an infection might seem to be a battle between David and Goliath, given the relative sizes of bacterial infectious agents and the animals they infect. But on closer examination it is more often a chess match between two skilled opponents who have the uncanny ability to anticipate each other's moves. An example is provided by the interaction between Mycobacterium tuberculosis, which causes tuberculosis (TB), and its human host. One of the host's first moves against the mycobacterium is the formation of a granuloma, an aggregate of cells, which consists of macrophages and other defensive immune cells. Although granulomas are required for the elimination of the infection, Lalita Ramakrishnan and colleagues have now shown that the bacteria have a game plan of their own.

One problem in understanding the interaction between the mycobacterium and the host has been that it occurs deep in the lung of the infected animal. To overcome this limitation, Ramakrishnan and colleagues used zebrafish embryos, which are transparent and can be infected by a relative of the TB pathogen, M. marinum. This enables the researchers to watch cells as they are recruited into the granuloma.

By visualizing in zebrafish infections of a virulent strain of M. marinum and a strain missing a genetic region called RD1 – a region that is somehow involved in the virulence of the bacteria – Ramakrishnan and colleagues have observed that RD1 is actually required for granuloma formation and even recruits more macrophages to granulomas. This might seem an odd strategy, as macrophages are required for mycobacterial elimination. But in this ongoing chess match, the virulent mycobacterium exploits the host's defense--granuloma formation--by providing additional macrophages for the bacteria to infect.

The end game of the chess match remains unclear. While granulomas are required for protection against mycobacteria, they are not completely effective. Thus, these bacteria have developed a strategy to recruit the normally defensive cells of the host to their advantage, but it remains to be shown what tips the balance between the macrophages' ability to clear the infection and their unwitting participation in the development of TB.

###

Citation: Volkman HE, Clay H, Beery D, Change JCW, Sherman DR, et al (2004) Tuberculous granuloma formation is enhanced by a Mycobacterium virulence determinant. PLoS Biol 2 (11): e367.


Story Source:

The above story is based on materials provided by Public Library Of Science. Note: Materials may be edited for content and length.


Cite This Page:

Public Library Of Science. "A Clear View Of Mycobacterial Infection." ScienceDaily. ScienceDaily, 5 November 2004. <www.sciencedaily.com/releases/2004/10/041030154143.htm>.
Public Library Of Science. (2004, November 5). A Clear View Of Mycobacterial Infection. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2004/10/041030154143.htm
Public Library Of Science. "A Clear View Of Mycobacterial Infection." ScienceDaily. www.sciencedaily.com/releases/2004/10/041030154143.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins